Literature DB >> 11315842

Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy.

B A Perkins1, D A Greene, V Bril.   

Abstract

OBJECTIVE: The aim of the current study was to determine the independent clinical risk factors for predicting morphological severity of distal diabetic sensorimotor polynecuropathy (DSP) as determined by fiber density (FD) on sural nerve biopsy. RESEARCH DESIGN AND METHODS: A total of 89 patients with both type 1 and type 2 diabetes, ascertained from a large therapeutic randomized clinical trial, were included in this observational cohort study. Morphological severity of DSP was expressed as the myelinated FD in the sural nerve biopsy General linear models were used to assess the relationship between the morphological severity of DSP and various clinical risk factors.
RESULTS: Glycated hemoglobin (GHb) was significantly related to FD in univariate and multivariate regression analyses. This relationship was present in models in which GHb was handled either as a continuous variable or as a categorical variable with the highest significance level, with a GHb cutoff level of 9%. After dividing patients into groups with optimal to moderate GHb < or = 9%) and suboptimal (GHb >9%) glycemic control, the difference in FD between the two groups ranged between 3,461 and 2,334 per mm2. FD was also significantly related to duration of diabetes and age of the patient.
CONCLUSIONS: The severity of peripheral DSP expressed by morphological criteria was significantly related to glycemic control in type 1 and type 2 diabetic patients. Inconsistent with previously published electrophysiological data demonstrating a correlation between height and conduction velocity, increasing height is not associated with morphological severity. Based on the results of the present study, it might be hypothesized that improving glycemic control will lessen severity of DSP in terms of FD loss in subjects with diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315842     DOI: 10.2337/diacare.24.4.748

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  13 in total

Review 1.  Treatments for diabetic neuropathy.

Authors:  A J Boulton
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 2.  Epidemiology of diabetes and diabetes-related complications.

Authors:  Anjali D Deshpande; Marcie Harris-Hayes; Mario Schootman
Journal:  Phys Ther       Date:  2008-09-18

3.  Pharmacological treatment of diabetic peripheral neuropathy.

Authors:  Kenneth Cohen; Nataliya Shinkazh; Jerry Frank; Igor Israel; Chris Fellner
Journal:  P T       Date:  2015-06

4.  The Role of Physical Therapists in Fighting the Type 2 Diabetes Epidemic.

Authors:  Marcie Harris-Hayes; Mario Schootman; Jeffrey C Schootman; Mary K Hastings
Journal:  J Orthop Sports Phys Ther       Date:  2019-11-28       Impact factor: 4.751

5.  Risk Factors For Diabetic Polyneuropathy.

Authors:  Yüksel Kaplan; Semiha Kurt; Hatice Karaer Ünaldi; Ünal Erkorkmaz
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

Review 6.  Diagnosis and management of diabetic neuropathy.

Authors:  Bruce A Perkins; Vera Bril
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  Biologic Basis of Nerve Decompression Surgery for Focal Entrapments in Diabetic Peripheral Neuropathy.

Authors:  John Sessions; D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2014-02-27

Review 8.  Criteria for creating and assessing mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; Stephen I Lentz; John L Roberts; Eva L Feldman
Journal:  Curr Drug Targets       Date:  2008-01       Impact factor: 3.465

9.  Chinese herbal medicine for diabetic peripheral neuropathy: an updated meta-analysis of 10 high-quality randomized controlled studies.

Authors:  Chi-zi Hao; Fan Wu; Lin Lu; Juan Wang; Yi Guo; Ai-ju Liu; Wei-jing Liao; Guo-qing Zheng
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Evaluation of proxy tests for SFSN: evidence for mixed small and large fiber dysfunction.

Authors:  Hamid Ebadi; Bruce A Perkins; Hans D Katzberg; Leif E Lovblom; Vera Bril
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.